Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development-Reference-Cited by-同舟云学术

Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development

Published:2021-05-27 Issue:11 Volume:64 Page:7261-7271
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Oronsky Bryan¹^ORCID,Guo XiaoNing²,Wang XiaoHui²,Cabrales Pedro³^ORCID,Sher David⁴,Cannizzo Lou⁵,Wardle Bob⁵,Abrouk Nacer¹,Lybeck Michelle¹,Caroen Scott¹,Oronsky Arnold⁶,Reid Tony R.¹

Affiliation:

1. EpicentRx Inc., 11099 North Torrey Pines Road, Suite 160, La Jolla, California 92037, United States

2. SciClone Pharmaceuticals Co., Ltd., 22 Floor, Shanghai Central Plaza, No. 381 Middle Huaihai Road, Huangpu, Shanghai 200020, China

3. Department of Bioengineering, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States

4. Department of Radiation Oncology, UT Southwestern Medical Center, 2280 Inwood Road, Dallas, Texas 75390, United States

5. Department of Space Systems, Northrop Grumman Corporation, 2980 Fairview Park Drive, Falls Church, Virginia 22042, United States

6. InterWest Partners, 467 First Street, Suite 201, Los Altos, California 94022, United States

Funder

EpicentRx, Inc.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00599

Reference75 articles.

1. Ning, S; Bednarski, M; Oronsky, B; Scicinski, J.; Saul, G; Knox, S. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Proceedings: 102nd Annual Meeting 2011, Apr 2–6, 2011, Orlando, FL; AACR. 2011; Vol. 71, 676.

2. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

3. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

4. Knox, S.; Ning, S.; Peehl, D.; Oronsky, B.; Scicinski, J. RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model. AACR-NCI-EORTC International Conference 2015: Molecular Targets and Cancer Therapeutics, November 5–9, 2011, Boston, MA; AACR-NCI-EORTC, 2015.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD40 agonist engineered immunosomes modulated tumor microenvironment and showed pro-immunogenic response, reduced toxicity, and tumor free survival in mice bearing glioblastoma;Biomaterials;2024-12

2. Small molecule innate immune modulators in cancer therapy;Frontiers in Immunology;2024-09-10

3. Dissoziative Elektronenanlagerungsdynamik eines vielversprechenden Krebsmedikaments zeigt sein Potential als Radiosensitizer;Angewandte Chemie;2024-09-06

4. Dissociative Electron Attachment Dynamics of a Promising Cancer Drug Indicates Its Radiosensitizing Potential;Angewandte Chemie International Edition;2024-09-06

5. Photodynamic Therapy Synergizes CD47 Blockade Strategy for Enhanced Antitumor Therapy;Molecular Pharmaceutics;2024-07-03